Radiofrequency and Exercise-based Rehabilitation on Symptoms Associated With Pelvic Floor Dysfunctions in Breast Cancer

Breast cancer has a high impact, affecting 2.3 million women worldwide in 2022. In Spain, there were 40,203 new cases in 2023. In addition to the economic and social costs, patients suffer genitourinary dysfunctions due to cancer treatments. Genitourinary Menopausal Syndrome (GUS) affects 50% of menopausal women, with a higher prevalence in women with breast cancer. This study aims to compare the effectiveness of radiofrequency (RF) and pelvic floor muscle exercise (PFMT) in the treatment of pelvic dysfunction associated with GUS in breast cancer patients. A randomised, double-blind clinical

Trial Details

NCT ID
NCT06694519
Phase
NA
Sponsor
SERGIO MONTERO NAVARRO
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • manometry through the PHENIX series device (model: PHENIX LIBERTY; manufacturer: ELECTRONIC CONCEPT LIGNON INNOVATION, Montpelier, France).
  • PFIQ-20 questionnaire (Pelvic Floor Impact Questionnaire Short Form)
  • ICIQ-SF (International Consultation on Incontinence Questionnaire - Short Form)
  • Sandvik's test
  • vaginal health index (VHI)
  • Visual analogue scale (VAS)
Locations (sample)
  • Elche, Spain / Valencia, Spain|38.26218,-0.70107

Key Eligibility Criteria

  • women of legal age with a clinical history of breast cancer, who agree to participate in the study and who present pelvic dysfunction assessed by t…
  • women survivors of stage 1 and 2 breast cancer
  • A medical discharge was granted more than one year ago
  • A diagnosis of another type of cancer has not been made.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →